Securing a Revenue Base and Developing New Core Business Pillars under the Next Medium-Term Management Plan
First written in FY2019. 5 of 12 entries say "Softened", first in FY2022. Latest entry: FY2026.
Seikagaku moved to the "Worse" side of this theme in 2022.
0 other companies' latest entry also says "Softened".
- FY2026SoftenedAnnual report
「Regarding future management policies, the company plans to reconsider them after obtaining the review results, as they will be affected by the results of the review of this product.」
The company stated that it would reconsider its management policies after the end of the medium-term management plan in light of the review results for SI-6603. - FY2025SoftenedAnnual report
「Going forward, we aim to resubmit SI-6603 within 1 year of receiving this notice. However, commercialization during the medium-term management plan period will be difficult, making it difficult to achieve the numerical targets of ¥40 billion in net sales and ¥7 billion in operating profit.」
The company indicated that the US launch of SI-6603, one of the medium-term management plan's priority initiatives, had become difficult during the plan period and that achieving the numerical targets would also be difficult. - FY2024AdvancedAnnual report
「In the fiscal year ending March 2024, progress in each priority initiative was generally in line with the plan. We will continue to work diligently on each priority initiative to build the capabilities needed to maintain a sustainable growth trajectory and achieve the targets set for the final year of the medium-term management plan.」
For the period for realizing growth from the fiscal year ending March 2023 through the fiscal year ending March 2026, the company reported progress in its priority initiatives for the fiscal year ending March 2024 and continued efforts toward the targets for the final year. - FY2023-Q3ReframedAnnual report
「We designated the 4-year period beginning in the fiscal year ending March 2023 as a period for realizing growth and formulated this medium-term management plan. By advancing each priority initiative on the foundation strengthened during the previous medium-term management plan, we aim to build the capabilities needed to maintain a growth trajectory and achieve record-high results in the final year.」
The next medium-term management plan, whose announcement had been postponed through the previous filing, was formulated and announced as a period for realizing growth from the fiscal year ending March 2023 through the fiscal year ending March 2026. The plan was repositioned as one that advances priority initiatives and targets record-high results in its final year. - FY2022SoftenedAnnual report
「Regarding the next medium-term management plan beginning in the fiscal year ending March 2023 and its numerical targets, we decided not to announce them as of May 2022 because the management plan and future earnings forecasts could change significantly depending on the progress of the safety measures currently being taken for Joyclu and developments concerning SI-6603, a treatment for lumbar disc herniation, in the United States. The next medium-term management plan is scheduled to be announced around autumn 2022.」
The announcement of the next medium-term management plan and numerical targets was postponed from the original schedule due to uncertainty surrounding Joyclu's safety measures and the US development of SI-6603. - FY2021AdvancedAnnual report
「In the current fiscal year, the second year of this medium-term management plan, we achieved a certain degree of progress in the priority initiatives despite unforeseen factors, including changes in the business environment resulting from the spread of COVID-19 and measures to contain its spread.」
For the second year of the medium-term management plan, the company reported the approval and launch of Joyclu, progress in the SI-722 trial, partnerships for SI-613 in China and South Korea, the launch of new LAL products, and progress in transferring manufacturing to Dalton as achievements. - FY2020AdvancedAnnual report
「In the current fiscal year, the first year of this medium-term management plan, there was a certain degree of progress in the 3 previously announced priority initiatives.」
For the first year of the medium-term management plan, the company reported progress in the 3 priority initiatives, including the submission of an approval application for SI-613, the start of Phase I/II trials for SI-722, the advancement of SI-449 to the pivotal trial stage, and the acquisition of Dalton as a subsidiary. - FY2020-Q3RestatedAnnual report
「We have positioned this medium-term management plan as a period for strengthening the revenue base needed to return the company to a growth trajectory and will pursue the following priority initiatives.」
The company continued its policy of positioning the medium-term management plan for the fiscal years ending March 2020 through March 2022 as a period for strengthening the revenue base toward renewed growth. - FY2020-Q2RestatedAnnual report
「We have positioned this medium-term management plan as a period for strengthening the revenue base needed to return the company to a growth trajectory and will pursue the following priority initiatives.」
The medium-term management plan for the fiscal years ending March 2020 through March 2022 was positioned as a period for strengthening the revenue base toward renewed growth, with priority initiatives including Hernicore, SI-613 and the LAL business being defined in concrete terms. - FY2019First statedAnnual report
「As securing a revenue base has become an urgent priority, we will devote all our efforts to bringing new core businesses, including SI-6603 (Hernicore) and SI-613, to fruition quickly and reliably within our core pharmaceutical business.」
Following the review of the previous medium-term management plan, the company first explicitly stated its direction of developing Hernicore and SI-613 as new core businesses and securing a revenue base as the framework of the next medium-term management plan.